Potentiation of the hypothalamic-pituitary-adrenal response to metyrapone by L-DOPA in acromegalic patients.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000172:Acromegaly / Q000503:physiopathology*; D000328:Adult; D003350:Cortodoxone / Q000031:analogs & derivatives / Q000652:urine; D005260:Female; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000503:physiopathology; D007980:Levodopa; D008297:Male; D008797:Metyrapone / Q000494:pharmacology*; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000503:physiopathology; D013268:Stimulation, Chemical
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D007980:Levodopa; D003350:Cortodoxone; D008797:Metyrapone